LEXINGTON, Mass. -- Findings presented at the 12th Conference on Retroviruses and Opportunistic Infections demonstrated that PRO 2000, a candidate topical microbicide under development by Indevus Pharmaceuticals, Inc., retains activity against the human immunodeficiency virus (HIV) and the herpes simplex virus (HSV) following intravaginal administration to HIV-infected women. These data were presented by Marla Keller, MD, assistant professor of medicine at the Mount Sinai School of Medicine, from a study funded by the National Institutes of Health (NIH) that marks the first time that the anti-viral activity of a microbicide has been demonstrated following human application. Microbicides are a class of products being developed to prevent sexually transmitted infections (STIs) when applied topically.
The Mount Sinai researchers conducted the prospective, randomized, double blind, placebo-controlled study among 20 HIV-infected women to assess the antiviral activity of PRO 2000 in cervicovaginal lavage (CVL) fluid collected before and one hour after administration of a single intravaginal dose of PRO 2000 gel or a matched placebo gel. CVL specimens were tested for their ability to prevent HIV and HSV infection of susceptible human cells in culture. Levels of inflammatory cytokines were also measured as markers of acute inflammation.
Analyses showed that CVL obtained after the application of PRO 2000 gel reduced both HIV and HSV infectivity by at least 1000-fold compared to CVL obtained at baseline. The effects were highly statistically significant (p<0.001). In contrast, CVL collected from placebo gel recipients showed little or no anti-viral effect. Furthermore, the researchers found similar low levels of inflammatory cytokines in CVL collected from the drug and placebo groups, indicating that PRO 2000 application did not induce an acute inflammatory response.
"To our knowledge, this is the first time a candidate topical microbicide has been shown to exhibit potent antiviral activity following human administration," said Dr. Keller. "The results indicate that PRO 2000 is sufficiently bioavailable and retains substantial anti-viral activity one hour after application of a single intravaginal dose. The retention of activity against both viruses is particularly significant in that HSV infection may increase the likelihood of HIV infection."
The effectiveness of PRO 2000 in preventing HIV and other sexually transmitted infections among at-risk women is to be assessed in two large clinical trials. A recently initiated NIH-sponsored study will enroll approximately 3,200 women at nine sites in Africa and the United States. In addition, a phase III clinical trial funded by the U.K. Department for International Development is due to start in 2005 and to include approximately 12,000 women in a number of African countries.
The Mount Sinai microbicide research team noted an urgent need for the development of safe and effective vaginal microbicides. While condoms offer protection against STIs, their effectiveness is limited because they require partner initiation or consent. According to the United Nations' 2004 report on the global AIDS epidemic, an estimated 40 million people worldwide are living with HIV, and women account for nearly half of those infected. As stated by the World Health Organization, unprotected sex is the predominant mode of HIV transmission, and genital herpes plays a major role in the sexual spread of HIV.
Source: Indevus Pharmaceuticals, Inc.
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.